Radiobiology and Imaging Program

项目摘要--放射生物学和成像方案(RBI) 放射生物学和成像计划(RBI)致力于促进对 电离和非电离辐射对癌症和正常组织的影响。RBI针对的是癌症负担 通过与我们的社区外联和参与(COE)合作，我们的集水区。科学 目标是：1)开发和表征改善放射治疗癌症的药物；2)调查 改变或询问免疫环境以提高治疗效果的放射生物学或成像方法 响应；3)加深对肿瘤微环境(TME)和代谢的了解 利用这一认识来改善治疗反应；4)开发新的成像技术，以最佳地指导 癌症护理；以及5)了解质子的生物学效应，以优化其临床使用并确定 哪些患者将从质子束治疗中受益最多。该项目由Amit Maity，医学博士，博士， 放射肿瘤学系教授兼执行副主席，医学博士Daniel Pryma， 放射学副教授、核医学系主任。Maity博士和Pryma博士 NCI资助的研究人员将他们的科学愿景带到这个计划中，该计划专注于基础和 翻译研究和开发由调查员发起的试验。自上次续订以来，该计划 领导者招募新的初级和高级科学家，增强协作同行评审资金，以及更多 干预性临床试验的收益增加了一倍以上，特别是由研究者发起的试验(构成 干预应计利润的91.6%)。Maity博士和Pryma博士扩大了该计划对成像方式的关注 并进一步加强了RBI放射生物学和成像之间的整合和相互作用。 一个主要的发展是质子的翻译和临床研究的实质性扩展。 心理治疗。RBI与其他ACC项目有关键的互动，包括肿瘤生物学、免疫生物学、 癌症治疗，乳腺癌，癌症控制，烟草和环境致癌，以及 儿科肿瘤学。44名计划成员代表宾夕法尼亚大学四所学校的七个部门。RBI 成员有1200万美元的研究拨款(年度直接成本)，其中1090万美元是同行评审和 700万美元由NCI提供资金。在此期间，计划成员撰写了654份与癌症有关的出版物 项目期。其中，27%是内部程序设计，35%是内部程序设计，是多程序设计 制度性的。RBI有36个R01等价物。计划成员累积了1476名受试者进行干预性试验， 3611名受试者接受非干预性试验。

PROJECT SUMMARY – Radiobiology and Imaging Program (RBI) The Radiobiology and Imaging Program (RBI) seeks to advance the understanding of the interaction of ionizing and non-ionizing radiation with cancer and normal tissues. RBI addresses the cancer burden within our catchment area through collaboration with our Community Outreach and Engagement (COE). Scientific Aims are to: 1) Develop and characterize agents to improve cancer therapy with radiation; 2) Investigate radiobiological or imaging methods of altering or interrogating the immune environment to improve therapeutic response; 3) Gain a deeper understanding of the tumor microenvironment (TME) and metabolism with the aim to leverage this understanding to improve therapeutic response; 4) Develop novel imaging to optimally guide cancer care; and 5) Understand the biological effects of protons to optimize their clinical use and determine which patients will benefit most from proton beam therapy. The Program is led by Amit Maity, MD, PhD, Professor and Executive Vice-Chair of the Department of Radiation Oncology, and Daniel Pryma, MD, Associate Professor of Radiology and Chief of the Division of Nuclear Medicine. Drs. Maity and Pryma are NCI-funded researchers who bring their scientific vision to this Program, which is focused on basic and translational research and the development of investigator-initiated trials. Since the last renewal, the Program Leaders recruited new junior and senior scientists, enhanced collaborative peer-reviewed funding, and more than doubled accruals to interventional clinical trials, especially investigator-initiated trials (which constitute 91.6% of interventional accruals). Drs. Maity and Pryma expanded the Program's focus on imaging modalities and theranostics and further enhanced the integration and interplay between radiobiology and imaging in RBI. A major development has been the substantial expansion of both translational and clinical studies of proton therapy. RBI has critical interactions with other ACC Programs including Tumor Biology, Immunobiology, Cancer Therapeutics, Breast Cancer, Cancer Control, Tobacco and Environmental Carcinogenesis, and Pediatric Oncology. The 44 Program members represent seven departments from four schools at Penn. RBI members have $12M in research grant funding (annual direct costs), of which $10.9M is peer-reviewed and $7M is NCI-funded. There were 654 cancer-related publications authored by Program members during the project period. Of these, 27% are intra-Programmatic, 35% are inter-Programmatic and 64% are multi- institutional. RBI has 36 R01-equivalents. Program members accrued 1,476 subjects to interventional trials, and 3,611 subjects to non-interventional trials.